Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $330

Benzinga · 17h ago
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $326 to $330.